Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
AMLX - Amylyx Pharmaceuticals, Inc.
Market Cap 1.53B P/E - EPS this Y -690.00% Ern Qtrly Grth -
Income -165.87M Forward P/E 8.03 EPS next Y 53.80% 50D Avg Chg -3.00%
Sales 298.76M PEG 0.00 EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 4.34 EPS next 5Y -230.20% 52W High Chg -46.00%
Recommedations 2.90 Quick Ratio 4.48 Shares Outstanding 68.08M 52W Low Chg 44.00%
Insider Own 14.35% ROA -28.28% Shares Float 49.19M Beta -0.62
Inst Own 86.58% ROE -51.22% Shares Shorted/Prior 1.26M/1.97M Price 22.80
Gross Margin 8.52% Profit Margin -55.52% Avg. Volume 1,136,504 Target Price 4.25
Oper. Margin 7,457.09% Earnings Date Aug 8 Volume 815,083 Change -2.48%
Healthcare | Biotechnology | United States
About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals, Inc. News
11/09/24 Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023)
11/08/24 Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
11/08/24 Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call
11/07/24 Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
11/04/24 Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
10/25/24 Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc
11:04 AM October 2024's US Penny Stocks Poised For Growth
10/19/24 Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments
10/18/24 Amylyx’s AMX0035 shows promise in Phase II Wolfram syndrome trial
10/18/24 Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
10/18/24 PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
10/17/24 Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
10/15/24 Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
10/09/24 Amylyx Pharmaceuticals Inc (AMLX) Q2 2024 Earnings Call Highlights: Strategic Pipeline ...
09/09/24 Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)
09/06/24 Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)
08/28/24 Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
08/12/24 Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
08/10/24 We Think Amylyx Pharmaceuticals (NASDAQ:AMLX) Can Easily Afford To Drive Business Growth
08/08/24 Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
AMLX Chatroom

User Image CatDog38 Posted - 1 hour ago

$AMLX back to looking 👀

User Image G101SPM Posted - 1 hour ago

$AMLX $5.29 DAC (dollar average cost) $1.86 (8.12.25). EXIT $10.00 BRIEF: - Goldman analyst Corinne Jenkins highlighted, "AMLX recently acquired GLP-1R antagonist avexitide from Eiger BioPharmaceuticals. note: The agent is expected to begin a pivotal Ph3 study in post-bariatric hypoglycemia (PBH) in 1Q25, with topline data expected in 2026, and has become a key driver of the investment thesis for AMLX, per our conversations. Data to-date is largely supportive of the agent demonstrating a clinical benefit for patients with PBH. Based on our review of the prevalent market of PBH coupled with conversations with physicians, we see a significant addressable market for new agents, and estimate peak sales for avexitide at $1B (PoS: 50%)."

User Image PenkeTrading Posted - 6 hours ago

I found you a Golden Cross on the daily chart of Amylyx Pharmaceuticals Inc. $AMLX #Amylyx #GoldenCross #NASDAQ

User Image mkt_screwed Posted - 23 hours ago

$AMLX reload at $5.00!

User Image CatDog38 Posted - 1 day ago

$AMLX back in at 5.10

User Image ajmore Posted - 1 day ago

$AMLX in 2023 pfizer $PFE offloaded their rare disease and gene based therapies development and research. In their statement, they made it clear they will work through outsourcing and acquisitions in the rare disease space.

User Image CatDog38 Posted - 1 day ago

$AMLX the MM’s never let anyone buy PM or AM just some crooks

User Image showtime1 Posted - 1 day ago

$AMLX Golden cross imminent just needs to hold and grind a little higher..Hold your core position and trade around it. Big gains coming.

User Image SilentBull69 Posted - 1 day ago

$AMLX So we get an upgrade to $12 today and then the stock drops makes perfect sense 🤦🏼‍♂️ What a corrupt market

User Image CatDog38 Posted - 1 day ago

$AMLX I had to jump out at 5.52 but

User Image Mulhollandr Posted - 2 days ago

$CLNN here we are and $AMLX is shooting up. 🤦‍♂️

User Image CatDog38 Posted - 2 days ago

$AMLX got back in at 5.22

User Image ajmore Posted - 2 days ago

$AMLX The % stats 👇 relate to the HI incidences post these procedures.

User Image ajmore Posted - 2 days ago

$AMLX The number of Bariatric surgeries performed every yest stands at 250k with the majority in the developed world. 32.6% of patients after the RYGB procedure, 22.6% after sleeve gastrectomy and 2.3% after gastric banding. Avexitide showed significant improvement (on insulin peak and rescue requirements) when trialled in phase 2 randomised placebo controlled crossover study on patients post Bariatric surgery. BofA estimated peak yearly revenue of 2bln by 2032 is not reflected by their target price of 12.

User Image Mrcocoloco Posted - 2 days ago

$AMLX

User Image bearishbull69 Posted - 2 days ago

$AMLX $10 stock minimum

User Image ajmore Posted - 2 days ago

$AMLX Targets will even go higher once accelerated reviews are granted. The avexitide data from both the PBH and CHI trials are highly significant. Analysts are only just beginning to realise the potential here.

User Image Holy_Xerxes Posted - 2 days ago

$AMLX hold the gains already wtf

User Image Contactgray Posted - 2 days ago

$AMLX the market is turning all green. Great way to start another bull week. 🚀

User Image imjustme3 Posted - 3 days ago

$AMLX

User Image EufemiaJanosek Posted - 3 days ago

$AMLX Are you ready? It's time to be first to catch the stock! Our Al Trading Engine, Holly, knows all the secret signs when Big Buyers start Buying! go:- 𝗮𝗶𝗮𝗹𝗲𝗿𝘁.𝘂𝘀

User Image Contactgray Posted - 3 days ago

$AMLX HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and raises the price target from $8 to $12.

User Image Contactgray Posted - 3 days ago

$AMLX Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) shares climbed 17% to $5.56 after Baird upgraded the stock from Neutral to Outperform and raised its price target from $3 to $11.

User Image Contactgray Posted - 3 days ago

$AMLX send it to 12 baby!!!

User Image showtime1 Posted - 3 days ago

$AMLX Mizuho will upgrade next..

User Image Contactgray Posted - 3 days ago

$AMLX someone wants this to soar!

User Image Contactgray Posted - 3 days ago

$AMLX 12 👀

User Image Contactgray Posted - 3 days ago

$AMLX is this going to happen? It’s look into looking good.

User Image Contactgray Posted - 3 days ago

$AMLX if this breaks 6 watch out!

User Image showtime1 Posted - 3 days ago

$AMLX Bought the fear friday and banking on Monday.

Analyst Ratings
Goldman Sachs Neutral Jul 12, 24
HC Wainwright & Co. Buy Jul 10, 24
HC Wainwright & Co. Buy Jun 24, 24
Mizuho Neutral May 14, 24
HC Wainwright & Co. Buy May 10, 24
Baird Neutral Apr 11, 24
HC Wainwright & Co. Buy Apr 11, 24
HC Wainwright & Co. Buy Apr 8, 24
HC Wainwright & Co. Buy Mar 12, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Klee Justin B. Co-Chief Executive O.. Co-Chief Executive Officer Jan 09 Sell 16.3281 5,841 95,372 2,836,776 01/11/24
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Jan 09 Sell 16.3281 2,716 44,347 112,035 01/11/24
Cohen Joshua B Co-Chief Executive O.. Co-Chief Executive Officer Jan 09 Sell 16.3281 5,841 95,372 2,900,470 01/11/24
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Jan 09 Sell 16.3281 2,812 45,915 205,605 01/11/24
Cohen Joshua B Co-Chief Executive O.. Co-Chief Executive Officer Nov 16 Option 1.57 63,694 100,000 2,906,311 11/20/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer May 16 Sell 27.26 32,500 885,950 55,676 05/18/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer May 16 Option 6.88 32,500 223,600 88,176 05/18/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Apr 17 Sell 30.74 49,579 1,524,058 208,417 04/19/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Apr 17 Option 3.63 49,579 179,972 257,996 04/19/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Mar 16 Sell 32.16 32,500 1,045,200 34,009 03/24/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Mar 16 Option 6.88 32,500 223,600 66,509 03/24/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Mar 16 Sell 32.14 54,627 1,755,712 199,250 03/24/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Mar 16 Option 2.53 49,578 125,432 253,877 03/24/23
Klee Justin B. Co-Chief Executive O.. Co-Chief Executive Officer Mar 16 Sell 32.16 100,000 3,216,000 2,792,617 03/20/23
MILNE GEORGE M JR Director Director Mar 16 Sell 32.15 35,000 1,125,250 862,021 03/20/23
Firestone Karen Director Director Mar 16 Buy 31.99 1,000 31,990 1,000 03/20/23
Cohen Joshua B Co-Chief Executive O.. Co-Chief Executive Officer Mar 16 Sell 32.14 100,000 3,214,000 2,792,617 03/20/23
Mazzariello Gina Chief Legal Officer Chief Legal Officer Feb 24 Sell 34.4874 3,586 123,672 37,414 02/28/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Jan 06 Sell 36.43 2,034 74,099 204,299 01/10/23
Cohen Joshua B Co-Chief Executive O.. Co-Chief Executive Officer Jan 06 Sell 36.43 5,968 217,414 2,892,617 01/10/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Jan 06 Sell 36.43 2,658 96,831 34,009 01/10/23
Olinger Margaret Chief Commercial Off.. Chief Commercial Officer Jan 06 Sell 36.43 2,403 87,541 214,355 01/10/23
Klee Justin B. Co-Chief Executive O.. Co-Chief Executive Officer Jan 06 Sell 36.43 5,968 217,414 2,892,617 01/10/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Dec 30 Option 6.88 5,000 34,400 36,667 01/04/23
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Sep 08 Sell 29.95 1,400,000 41,930,000 1,850,940 09/09/22
ALS Invest 1 B.V. 10% Owner 10% Owner Jul 06 Sell 20.97 60,609 1,270,971 5,895,280 07/08/22
Morningside Venture Investment... 10% Owner 10% Owner Jan 06 Buy 19 263,158 5,000,002 10,678,808 03/17/22
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jan 11 Buy 19 2,300,000 43,700,000 2,300,000 01/13/22
FONTEYNE PAUL R. Director Director Jan 06 Buy 19.00 3,947 74,993 3,947 01/10/22
Cheng Isaac Director Director Jan 06 Buy 19 6,578 124,982 6,578 01/10/22
MILNE GEORGE M JR Director Director Jan 06 Buy 19.00 26,315 499,985 221,396 01/10/22
Olinger Margaret Chief Commercial Off.. Chief Commercial Officer Jan 06 Buy 19 6,842 129,998 216,758 01/10/22